Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab

NCT04495478 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04495478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
July 30, 2020
Completion date
May 9, 2021
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy